Numinus Congratulates MAPS on Phase 3 Clinical Trial of MDMA for severe PTSD

1 in 11 Canadians will suffer from PTSD in their lifetime. We urgently need new approaches to mental health care – and now we’re getting closer. Numinus and Dr. Devon Christie, Our Medical & Therapeutic Services Director, congratulate the Multidisciplinary Association for Psychedelic Studies (MAPS) and the MAPP1 trial study team for the strong results from the Phase 3 randomized clinical trial of MDMA-assisted therapy for the treatment of severe post-traumatic stress disorder (PTSD).

The trial involved 90 participants with chronic PTSD. It demonstrated that 88% of participants who received three controlled and supervised MDMA-assisted therapy sessions experienced a clinically significant reduction in symptoms, with 67% no longer qualifying for PTSD diagnosis in comparison to 32% of participants randomized to placebo. Study participants had PTSD diagnoses from a range of causes, including combat-related events, accidents, abuse, sexual harm and developmental trauma.

With these results, researchers and regulators alike now have more data on treatment safety and efficacy. Dr. Christie explains why this groundbreaking study holds such promise for people suffering from PTSD.